Keyword: Bausch & Lomb

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

A former Valeant executive suspected an illicit relationship between a colleague and mail order pharmacy Philidor, he testified.

Valeant is getting a new name and stock ticker to press ahead after its storied downfall.

Valeant has overcome manufacturing problems at a Bausch & Lomb plant to win approval of its long-delayed eye drug.

A mutual fund that says it lost a mind-boggling $80 billion investing in Valeant alleges in a lawsuit that Valeant was a criminal enterprise.

Valeant hit back against eye-device maker Icon in legal fight over proprietary lens technology.

Valeant Pharmaceuticals has added famed hedge fund manager John Paulson to its board.

Valeant is in talks to sell its Bausch & Lomb eye surgery business to Carl Zeiss Meditec for potentially $2 billion, Bloomberg reports.

Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, triggering a 20% run-up in its share price.

Valeant Pharmaceuticals International said today that it has gotten a new PDUFA date for its eye drug candidate latanoprostene bunod, which the FDA sidelined last year because of manufacturing concerns.